Sponsor: 
Pfizer Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Pneumococcal conjugate vaccine

Registered for use in children aged ≥6 weeks and in adults.

13vPCV — 13-valent pneumococcal conjugate vaccine

Each 0.5 mL monodose pre-filled syringe contains:

  • 2.2 µg each of pneumococcal capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F
  • 4.4 µg of pneumococcal capsular polysaccharide of serotype 6B
  • succinic acid
  • polysorbate 80

Antigens are conjugated to non-toxic Corynebacterium diphtheriae CRM197 protein and adsorbed onto 0.565 mg aluminium phosphate.

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

13vPCV
13-valent pneumococcal conjugate vaccine